Supriya Lifescience Intrinsic Value
SUPRIYA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹499.40 | ₹399.52 - ₹599.28 | -34.7% | EPS: ₹22.70, Sector P/E: 22x |
| Book Value Method | asset | ₹1246.25 | ₹1121.62 - ₹1370.88 | +62.9% | Book Value/Share: ₹623.12, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹906.25 | ₹815.62 - ₹996.88 | +18.5% | Revenue/Share: ₹453.12, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1530.00 | ₹1377.00 - ₹1683.00 | +100.0% | EBITDA: ₹269.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1400.78 | ₹1120.62 - ₹1680.94 | +83.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹229.50 | ₹206.55 - ₹252.45 | -70.0% | EPS Growth: 4.7%, Fair P/E: 3.8x |
| Growth Adjusted P/E | growth | ₹353.68 | ₹318.31 - ₹389.05 | -53.8% | Revenue Growth: 7.7%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹1530.00 | ₹1377.00 - ₹1683.00 | +100.0% | ROE: 18.3%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹564.15 | ₹507.74 - ₹620.57 | -26.3% | EPS: ₹22.70, BVPS: ₹623.12 |
Want to compare with current market value? Check SUPRIYA share price latest .
Valuation Comparison Chart
SUPRIYA Intrinsic Value Analysis
What is the intrinsic value of SUPRIYA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Supriya Lifescience (SUPRIYA) is ₹906.25 (median value). With the current market price of ₹765.00, this represents a +18.5% variance from our estimated fair value.
The valuation range spans from ₹229.50 to ₹1530.00, indicating ₹229.50 - ₹1530.00.
Is SUPRIYA undervalued or overvalued?
Based on our multi-method analysis, Supriya Lifescience (SUPRIYA) appears to be trading below median value by approximately 18.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.24 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.12 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 18.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Supriya Lifescience
Additional stock information and data for SUPRIYA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹165 Cr | ₹89 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹26 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹64 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹49 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹76 Cr | ₹53 Cr | Positive Free Cash Flow | 8/10 |